Comment

  • 27 March 2018

    Global osteoporosis market to reach $11.2bn by 2027

    Despite being a market dominated by generic bisphosphates, the osteoporosis market is likely to undergo significant changes over the next 10 years, growing at a compound annual growth rate of...

  • 27 March 2018

    Rituximab biosimilars: is the hype warranted?

    The biosimilars market is awash with excitement. While these copycat biologic products create competition with the originator drugs, reducing costs and increasing healthcare savings, their efficacy and safety risks should...

  • 21 March 2018

    Pfizer’s rituximab biosimilar edges closer to approval

    Pfizer’s rituximab biosimilar candidate, PF-05280586, edged closer towards approval on January 24, 2018, when the company announced positive top-line results in a Phase III trial in follicular lymphoma (FL).

Close
Close
Close

Go Top